IRIS
2003
International Randomized Study of Interferon and STI571
In 1,106 patients with newly diagnosed chronic-phase CML, imatinib improved cytogenetic response and progression-free survival compared with interferon-α + cytarabine.
Result
- Absolute difference
- 61.7 points
The absolute difference is derived from the event rates.
Also reported: 10-yr OS 83.3%; 10-yr complete cytogenetic response in 82.8%.
- Subtopic
- Chronic myeloid leukaemia
- Design
- Open-label RCT
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- O'Brien SG, et al. N Engl J Med. 2003;348(11):994-1004; Hochhaus A, et al. N Engl J Med. 2017;376(10):917-927.doi 10.1056/NEJMoa022457
Discussion & critique
Transformed CML from a uniformly fatal disease to one with near-normal life expectancy. Foundation for the entire BCR-ABL TKI class.